- Home
- OPI vs IGC Comparison
OPI vs IGC Comparison
Compare OPI & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPI
- IGC
- Stock Information
- Founded
- OPI 2009
- IGC 2005
- Country
- OPI United States
- IGC United States
- Employees
- OPI N/A
- IGC N/A
- Industry
- OPI Real Estate Investment Trusts
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- OPI Real Estate
- IGC Health Care
- Exchange
- OPI Nasdaq
- IGC Nasdaq
- Market Cap
- OPI 16.9M
- IGC 20.2M
- IPO Year
- OPI 2009
- IGC N/A
- Fundamental
- Price
- OPI $0.19
- IGC $0.31
- Analyst Decision
- OPI
- IGC Strong Buy
- Analyst Count
- OPI 0
- IGC 2
- Target Price
- OPI N/A
- IGC $3.88
- AVG Volume (30 Days)
- OPI 1.1M
- IGC 203.3K
- Earning Date
- OPI 04-30-2025
- IGC 06-23-2025
- Dividend Yield
- OPI 20.52%
- IGC N/A
- EPS Growth
- OPI N/A
- IGC N/A
- EPS
- OPI N/A
- IGC N/A
- Revenue
- OPI $476,159,000.00
- IGC $1,236,000.00
- Revenue This Year
- OPI N/A
- IGC N/A
- Revenue Next Year
- OPI N/A
- IGC $16.45
- P/E Ratio
- OPI N/A
- IGC N/A
- Revenue Growth
- OPI N/A
- IGC 1.65
- 52 Week Low
- OPI $0.18
- IGC $0.25
- 52 Week High
- OPI $3.02
- IGC $0.55
- Technical
- Relative Strength Index (RSI)
- OPI 28.91
- IGC 52.27
- Support Level
- OPI $0.25
- IGC $0.28
- Resistance Level
- OPI $0.30
- IGC $0.32
- Average True Range (ATR)
- OPI 0.02
- IGC 0.02
- MACD
- OPI 0.01
- IGC 0.00
- Stochastic Oscillator
- OPI 10.83
- IGC 40.67
About OPI Office Properties Income Trust of Beneficial Interest
Office Properties Income Trust is a United States-based real estate investment trust. Its property portfolio is mainly composed of single-tenant office buildings, as well as multitenant properties, which are leased to parties of high credit quality characteristics. Its major tenant is the U.S. government, followed by other smaller government entities and corporations. The company's properties are spread across the United States. The company has only one segment which is direct ownership of real estate properties.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.